Cell Growth & Differentiation, Vol 6, Issue 12 1567-1577, Copyright © 1995 by American Association of Cancer Research

ARTICLES

Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells

RJ Fiddes, PW Janes, GM Sanderson, SP Sivertsen, RL Sutherland and RJ Daly
Co-operative Research Centre for Biopharmaceutical Research, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, New South Wales, Australia.

The heregulins (HRGs) are a family of growth factors that bind direction to erbB3 and erbB4 and induce tyrosine phosphorylation of erbB2 via receptor heterodimerization. Since erbB2, erbB3, and erbB4 (erbB2-4) are often overexpressed in human breast cancer cells, we produced recombinant HRGs and a HRG-based ligand toxin to investigate the signaling events triggered by HRGs and the ability of these ligands to specifically target such cells. Recombinant HRG beta 2 stimulated the tyrosine phosphorylation of erbB2-4 in ZR-75-1 human breast cancer cells. This was accompanied by the tyrosine phosphorylation of Shc and the formation of complexes between Shc and the adapter protein Grb2. Complexes were also detected between Shc and erbB2-4. However, GRb2 was detected in erbB2 and erbB4 but not erbB3 immunoprecipitates. Thus, these receptors exhibit mechanistic differences in their coupling to Ras signaling, and HRG beta 2 administration triggers multiple inputs into the Ras signaling pathway, involving receptor-Grb2, receptor-Shc, and Shc-Grb2 complexes. HRG beta 2 addition also stimulated the association of erbB3 with phosphatidylinositol-3-kinase. In accordance with the activation of key mitogenic signaling pathways, HRG beta 2 stimulated the proliferation of MCF-7 and T-47D human breast cancer cells. Moreover, when tested for the ability to stimulate cell cycle re-entry of T-47D cells arrested under serum-free conditions, HRG beta 2 was more effective than insulin, previously the most potent mitogen identified using this system. Finally, a HRG beta 2 PE40 ligand toxin was constructed and found to exhibit cytotoxic activity against human breast cancer cells overexpressing erbB3 alone or in combination with erbB4 and/or erbB2.

This article has been cited by other articles:

				F. A. Stennard, M. W. Costa, D. Lai, C. Biben, M. B. Furtado, M. J. Solloway, D. J. McCulley, C. Leimena, J. I. Preis, S. L. Dunwoodie, et al. Murine T-box transcription factor Tbx20 acts as a repressor during heart development, and is essential for adult heart integrity, function and adaptation Development, May 15, 2005; 132(10): 2451 - 2462. [Abstract] [Full Text] [PDF]

				M. Keir, R. Fiddes, J. C. Biggs, and P. P. Kearney Sensitivity of c-erbB Positive Cells to a Ligand Toxin and Its Utility in Purging Breast Cancer Cells from Peripheral Blood Stem Cell (PBSC) Collections Stem Cells, November 1, 2000; 18(6): 422 - 427. [Abstract] [Full Text]

				A. Swarbrick, C. S. L. Lee, R. L. Sutherland, and E. A. Musgrove Cooperation of p27Kip1 and p18INK4c in Progestin-Mediated Cell Cycle Arrest in T-47D Breast Cancer Cells Mol. Cell. Biol., April 1, 2000; 20(7): 2581 - 2591. [Abstract] [Full Text]

				R. J. Fiddes, D. H. Campbell, P. W. Janes, S. P. Sivertsen, H. Sasaki, C. Wallasch, and R. J. Daly Analysis of Grb7 Recruitment by Heregulin-activated erbB Receptors Reveals a Novel Target Selectivity for erbB3 J. Biol. Chem., March 27, 1998; 273(13): 7717 - 7724. [Abstract] [Full Text] [PDF]